Skip to main content

Bessemer Venture Partners IX Institutional L.P.'s Form 4 filing

NeueHealth, Inc. (NEUE) · filed Oct 19, 2022

Accession no.
0001209191-22-054154
Filed
Oct 19, 2022, 8:59 PM ET
Trade date
Oct 17, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 derivative transaction. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bessemer Venture Partners IX Institutional L.P.CIK 000162414910% Owner
Bessemer Venture Partners IX L.P.CIK 000165521310% Owner
Deer IX & Co. L.P.CIK 000165521910% Owner
Deer IX & Co. Ltd.CIK 000165522010% Owner
15 Angels II LLCCIK 000171325710% Owner
Deer X & Co. L.P.CIK 000176863710% Owner
Deer X & Co. Ltd.CIK 000176867710% Owner
Bessemer Venture Partners Century Fund Institutional L.P.CIK 000178747710% Owner
Bessemer Venture Partners Century Fund L.P.CIK 000178747810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 17, 2022Common StockPPurchaseAcquired+5,998,851$1,000.00F1+$8,500,0008,500Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The Issuer's Series B Convertible Perpetual Preferred Stock ("Preferred Stock") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of Issuer's common stock ("Common Stock") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $1.4169) as of the applicable conversion date, subject to anti-dilution adjustments.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)